Klin Farmakol Farm. 2005;19(1):59-60

Angiotensin-converting-enzyme in stable coronary artery disease

Jiří Vítovec¹, doc. MUDr. Jindřich Špinar CSc²

¹ I. interní kardioangiologická klinika FN u sv. Anny v Brně

² II. interní klinika FN u sv. Anny LF MU, Brno

The PEACE study (Prevention of Events with Angiotensin Converting Enzyme Inhibition Trial) is a multicentric randomized, double blind study, comparing the treatment with ACE inhibitor trandolapril to placebo in patients with confirmed ischemic heart disease without heart failure, with ejection fraction over 0.4 and BPd < 100 mmHg. 8 290 patients were enrolled and followed for 4.8 years. The primary endpoint (death, nonfatal MI, CABG and PCI) was not influenced (21.9% vs. 22.5%, p = 0.43). There was a decrease of hospitalizations or death due to heart failure (2.8% vs. 3.7%, p = 0.02) and a decrease of new cases of diabetes mellitus (9.8% vs. 11.5%, p < 0.01). 72% of the patients were after revascularization and 70% were taking hypolipidemic treatment drugs.

Keywords: Key words: coronary artery disease, ACE inhibitors, secondary prevention.

Published: January 1, 2006  Show citation